1 hr. 2 min.


Part 1 of a 2-part webinar series, supported by AstraZeneca

During this webinar, the expert panel will discuss two recently published clinical trials (CALGB 140503 and JCOG 0802) that demonstrate equivalent survival for sublobar resection versus lobectomy for clinical stage IA cancer, peripheral <2cm. While both trials showed similar results, there are important differences in design, demographics, and patients’ outcomes. The presenters will debate the nuances of the trials and their potential applications in clinical practice. 

View Part 2 : "Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC." 


Robert E. Merritt, MD
The Ohio State University
Columbus, OH

Sandra L. Starnes, MD
University of Cincinnati Medical Center
Cincinnati, OH

Hari B. Keshava, MD
University of California, Irvine
Irvine, CA


Pro Sublobar Resection
Daniel L. Miller, MD
Medical College of Georgia
Augusta, GA

Con Sublobar Resection
Scott J. Swanson, MD
Brigham and Women's Hospital
Boston, MA